Antimicrobials
Azithromycin

Azithromycin

Medium
Excellent
IV-$9/d PO-$1/d

Spectrum of Activity

General Information

  • Community acquired pneumonia
  • Pertussis
  • Upper respiratory tract infections
  • Chlamydial infections
  • Mycobacterial infections

Monitor QTc in patients with increased risk.

Prolongation of QTc interval.

Orally administered azithromycin, when given in the first 6 weeks of life, is associated with increased risk of infantile hypertrophic pyloric stenosis (IHPS), therefore clinicians need to weigh benefits and risks when considering its use. Azithromycin however remains the drug of choice for treatment or prophylaxis of pertussis in very young infants. Cases of IHPS in young infants who have been treated with a macrolide antibiotic should be reported to Health Canada.

While less risk of interaction compared to other macrolides, several potential CYP450 interactions may occur; consult a pharmacist for for more details.

Avoid concurrent use with other drugs that prolong QTc.

Concentration: 40 mg/mL
Taste: bitter

Not all strengths of oral liquids are listed nor are available on IWK formulary

  • 250 mg tablet
  • Tablets and capsules are preferred especially over an unpleasant tasting liquid
  • Not all strengths of oral tablets/capsules are listed and they are not all available on the IWK formulary

Antimicrobial class: Macrolide

Average serum half life:

  • Pediatrics: 54.5 hours

Route of Elimination:

  • 50% excreted unchanged in bile
  • 6-14% excreted unchanged in urine